羟氯喹联合半量激素与足量激素治疗IgA肾病的比较

doi:10.3969/j.issn.1000-8535.2023.10.005

摘要/Abstract

摘要： 目的对比羟氯喹联合半量激素与足量糖皮质激素（激素）治疗IgA肾病在减少尿蛋白、保护肾功能方面的效果以及不良反应的发生率。方法筛选2020年6月—2022年1月我院收治基线尿蛋白排泄量>1 g/ d、基线估算肾小球滤过率>15 mL/min的IgA肾病患者为研究对象,随机分为羟氯喹+半量激素（Q+G）组及足量激素（G）组。Q+G组予羟氯喹及泼尼松0.5 mg/（kg·d）,G组予泼尼松 1 mg/（kg·d）,比较2组在治疗2、4、6个月后24 h尿蛋白定量的改变值;比较2组6个月内24 h尿蛋白较基线下降>30%的比例、24 h尿蛋白定量下降至1 g以下的比例、估算肾小球滤过率下降>30%的比例以及不良反应发生率。结果纳入Q+G组49例,G组46例。2组在治疗2、4、6个月后的24 h尿蛋白定量改变值、6个月内24 h尿蛋白较基线下降>30%的比例、24 h尿蛋白定量下降至1 g以下的比例、6个月内估算肾小球滤过率下降>30%的比例比较差异均无统计学意义（均P>0.05）;Q+G组不良反应发生率低于G组（P<0.05）。结论与足量激素治疗相比,羟氯喹联合半量激素治疗尿蛋白持续>1 g/d的IgA肾病患者在减少尿蛋白、保护肾功能中的效果相近,而不良反应的发生率较低。

关键词: 羟氯喹, 糖皮质激素, IgA肾病, 24 h尿蛋白定量, 肾功能, 不良反应

Abstract: Objective Compared with full-dose glucocorticoid,to evaluate the effect of hydroxychloroquine combined with half-dose glucocorticoid in the treatment of IgA nephropathy in reducing urinary protein and protecting renal function,as well as the incidence of adverse reactions. Methods From June 2020 to January 2022,patients with IgA nephropathy whose baseline urinary protein excretion>1 g/d and baseline estimate glomerular filtration rate>15 mL/min were enrolled and randomly divided into hydroxychloroquine combined with half-dose glucocorticoid(Q+G)group and full-dose glucocorticoid(G)group. Each patient in Q+G group was given oral hydroxychloroquine and oral prednisone at a dose of 0. 5 mg/(kg·d). Each patient in G group was given prednisone at a dose of 1 mg/(kg·d). The changes in 24-hour urine protein quantification between the two groups at 2,4 and 6 months of treatment were compared;the proportions of 24-hour urine protein decreased by more than 30%,24-hour urine protein decreased to less than 1 g,estimate glomerular filtration rate decreased >30% and adverse reactions within 6 months were compared between the two groups. Results Fourty-nine cases were enrolled in Q+G group and 46 cases in G group. There was no significant difference in the 24-hour urine protein changes between the two groups at 2,4 and 6 months of treatment. The proportion of 24-hour urine protein decreased by 30%,the proportion of the 24-hour urine protein decreased to below 1 g and the proportions of patients whose estimate glomerular filtration rate decreased by >30% within 6 months between the two groups were not significantly different. The proportion of adverse reactions in Q+G group was lower than that in G group. Conclusions Hydroxychloroquine combined with half-dose glucocorticoid has similar effects in reducing urinary protein and protecting renal function and lowering incidence of adverse reactions compared with full-dose glucocorticoid therapy in the treatment of patients with IgA nephropathy whose urinary protein excretion > 1 g/d.

Key words: hydroxychloroquine, glucocorticoid, IgA nephropathy, 24-hour urine protein, renal function, adverse reaction

谭嘉臻, 廖纯兴, 向冬梅, 薛志强. 羟氯喹联合半量激素与足量激素治疗IgA肾病的比较[J]. 广州医药, 2023, 54(10): 39-45.

TAN Jiazhen, LIAO Chunxing, XIANG Dongmei, XUE Zhiqiang. Comparison of hydroxychloroquine combined with half-dose glucocorticoid and full-dose glucocorticoid in the treatment of IgA nephropathy[J]. Guangzhou Medical Journal, 2023, 54(10): 39-45.

参考文献

[1] LAI K N,TANG S C,SCHENA F P,et al.IgA nephropathy[J].Nat Rev Dis Primers,2016(2):16001.
[2] 肖永真,杨晓.羟氯喹在IgA肾病中的应用[J].临床肾脏病杂志,2021,21(3):253-257.
[3] Kidney Disease:Improving Global Outcomes(KDIGO)Glomerular Diseases Work Group.KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J].Kidney Int,2021,100(4S):S1-S276.
[4] LAI K N.Pathogenesis of IgA nephropathy[J].Nat Rev Nephrol,2012,8(5):275-283.
[5] YEO S C,CHEUNG C K,BARRATT J.New insights into the pathogenesis of IgA nephropathy[J].Pediatr Nephrol,2018,33(5):763-777.
[6] DURCAN L,PETRI M.Immunomodulators in SLE:Clinical evidence and immunologic actions[J].J Autoimmun,2016(74):73-84.
[7] 魏凯悦,米焱.羟氯喹治疗IgA肾病的研究进展[J].肾脏病与透析肾移植杂志,2022,31(3):266-270.
[8] 李优,姜红,李维.羟氯喹对IgA肾病大鼠肾脏病理和Toll样受体4表达的影响[J].中国医科大学学报,2020,49(11):997-1001.
[9] LIU L J,YANG Y Z,SHI S F,et al.Effects of hydroxychloroquine on proteinuria in IgA nephropathy:a randomized controlled trial[J].Am J Kidney Dis,2019,74(1):15-22.
[10] 潘怡璇,陈肖蓉,任萍萍,等.羟氯喹治疗IgA肾病疗效与安全性的单中心回顾性分析[J].中华肾脏病杂志,2022,38(2):81-90.
[11] 彭露婷,黄志荣,官慧儿,等.羟氯喹补充治疗IgA肾病安全性和有效性的系统评价[J].中国医院药学杂志,2022,42(14):1463-1468.
[12] 刘密迦,李贵森.羟氯喹联合治疗对IgA肾病残余蛋白尿的影响[J].实用医院临床杂志,2021,18(2):142-145.
[13] YANG Y Z,CHEN P,LIU L J,et al.Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy:a case-control study[J].BMC Nephrol,2019,20(1):297.
[14] 王超超,林永强,蔡小巧,等.羟氯喹与糖皮质激素治疗IgA肾病效果比较[J].浙江医学,2022,44(5):523-525.
[15] 蔡增苗. 激素联合羟氯喹治疗IgA肾病的效果[J].中国现代药物应用,2022,16(15):112-115.